Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors.
Jacob MoraCentro Científico y Tecnológico de Excelencia Ciencia & Vida, Fundación Ciencia & Vida, Avenida Del Valle Norte #725, Huechuraba, Santiago 8580702, Chile.
Iu RaïchDepartmento de Bioquímica y Fisiología, Facultad de Farmacia y Ciencia de los Alimentos, Universidad de Barcelona, 08028 Barcelona, Spain.ORCID 0000-0001-6271-0495
Valentina UgaldeCentro Científico y Tecnológico de Excelencia Ciencia & Vida, Fundación Ciencia & Vida, Avenida Del Valle Norte #725, Huechuraba, Santiago 8580702, Chile.
Gemma NavarroDepartmento de Bioquímica y Fisiología, Facultad de Farmacia y Ciencia de los Alimentos, Universidad de Barcelona, 08028 Barcelona, Spain.ORCID 0000-0003-4654-0873
Carolina PradoCentro Científico y Tecnológico de Excelencia Ciencia & Vida, Fundación Ciencia & Vida, Avenida Del Valle Norte #725, Huechuraba, Santiago 8580702, Chile.ORCID 0000-0001-7015-9058
Pia M VidalNeuroimmunology and Regeneration of the Central Nervous System Unit, Biomedical Science Research Laboratory, Basic Sciences Department, Faculty of Medicine, Universidad Católica de la Santísima Concepción, Concepción 4080000, Chile.ORCID 0000-0001-9885-3076
Pedro LealCentro Científico y Tecnológico de Excelencia Ciencia & Vida, Fundación Ciencia & Vida, Avenida Del Valle Norte #725, Huechuraba, Santiago 8580702, Chile.
Alexandra EspinozaCentro Científico y Tecnológico de Excelencia Ciencia & Vida, Fundación Ciencia & Vida, Avenida Del Valle Norte #725, Huechuraba, Santiago 8580702, Chile.
Moting LiuDepartment of Gastroenterology and Hepatology, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands.
Rinse WeersmaDepartment of Gastroenterology and Hepatology, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands.
Ranko GacesaDepartment of Gastroenterology and Hepatology, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands.ORCID 0000-0003-2119-0539
Marcela A HermosoDepartment of Gastroenterology and Hepatology, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands.
Rafael FrancoCentro de Investigación en Red, Enfermedades Neurodegenerativas (CiberNed), Instituto de Salud Carlos III, 28029 Madrid, Spain.ORCID 0000-0003-2549-4919
Rodrigo PachecoCentro Científico y Tecnológico de Excelencia Ciencia & Vida, Fundación Ciencia & Vida, Avenida Del Valle Norte #725, Huechuraba, Santiago 8580702, Chile.ORCID 0000-0001-8057-9806
Funding
Agencia Nacional de Investigación y Desarrollo de Chile FB210008Agencia Nacional de Investigación y Desarrollo de Chile FONDECYT 1210013Agencia Nacional de Investigación y Desarrollo de Chile FONDECYT 1250021
6 · The paper itself
Abstract
Since colonic dopamine levels are markedly reduced during inflammatory bowel disease (IBD), we investigated how dopamine affects regulatory T-cells (Treg), which critically limit gut inflammation. Previously, we showed that the stimulation of the high-affinity dopamine receptor D
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The Heteromeric Dopamine Receptor D2:D3 Controls the Gut Recruitment and Suppressive Activity of Regulatory T-Cells. · full record | OpenQuestion